ロード中...
Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
Diabetes Mellitus continues to be a major non- communicable disease with global burden of 366 million at present and projected to increase to 439 to 552 million by 2030, India being the hub of diabetes. Sodium glucose transporter 2 (SGLT2) inhibitors presents a new class of anti-diabetic drugs havin...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Medknow Publications & Media Pvt Ltd
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3978932/ https://ncbi.nlm.nih.gov/pubmed/24741548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1947-2714.128471 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|